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Hereditary angioedema (HAE) is a disease which is associated with random and often unpredictable attacks of
painful swelling typically affecting the extremities, bowel mucosa, genitals, face and upper airway. Attacks are
associated with significant functional impairment, decreased Health Related Quality of Life, and mortality in the case
of laryngeal attacks. Caring for patients with HAE can be challenging due to the complexity of this disease. The care
of patients with HAE in Canada is neither optimal nor uniform across the country. It lags behind other countries
where there are more organized models for HAE management, and where additional therapeutic options are
licensed and available for use. The objective of this guideline is to provide graded recommendations for the
management of patients in Canada with HAE. This includes the treatment of attacks, short-term prophylaxis,
long-term prophylaxis, and recommendations for self-administration, individualized therapy, quality of life, and
comprehensive care. It is anticipated that by providing this guideline to caregivers, policy makers, patients and their
advocates, that there will be an improved understanding of the current recommendations regarding management
of HAE and the factors that need to be considered when choosing therapies and treatment plans for individual
patients. The primary target users of this guideline are healthcare providers who are managing patients with HAE.
Other healthcare providers who may use this guideline are emergency physicians, gastroenterologists, dentists and
otolaryngologists, who will encounter patients with HAE and need to be aware of this condition. Hospital
administrators, insurers and policy makers may also find this guideline helpful.
Keywords: Hereditary angioedema, Guideline, Recommendations, Acute attacks, Short-term prophylaxis, Long-term
prophylaxis, Self-administration, Individualized therapy, Quality of life, Comprehensive care, GRADE* Correspondence: betschels@smh.ca
1University of Toronto, Toronto, Ontario, Canada
Full list of author information is available at the end of the article
© 2014 Betschel et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Betschel et al. Allergy, Asthma & Clinical Immunology 2014, 10:50 Page 2 of 18
http://www.aacijournal.com/content/10/1/50Introduction
Background
Hereditary angioedema due to C1 inhibitor deficiency
(C1-INH-HAE) is an autosomal dominant condition with
an estimated prevalence of approximately 1:50,000 [1,2].
It results in random and often unpredictable attacks of
painful swelling typically affecting the extremities, bowel
mucosa, genitals, face and upper airway [3]. Attacks are
associated with significant functional impairment, de-
creased Health Related Quality of Life (HRQoL), and mor-
tality in the case of laryngeal attacks [4,5]. The swelling in
HAE is a result of impaired regulation of bradykinin syn-
thesis [6]. Bradykinin is a nonapeptide kinin formed from
high molecular weight kininogen by the action of plasma
kallikrein. Bradykinin is a very powerful vasodilator and
increases capillary permeability, constricts smooth muscle
and stimulates pain receptors [1].
HAE can be categorized into 3 different types depend-
ing on the level and function of C1inhibitor (C1-INH):
type 1(HAE-1), type 2 (HAE-2), and HAE with normal
C1-INH function (HAE-nC1INH) previously referred to
as type 3 (Table 1). HAE-1 is the most prevalent, repre-
senting approximately 85% of cases and results from low
antigenic and functional levels of C1-INH. HAE-2 ac-
counts for approximately 15% of cases and is associated
with a normal C1-INHprotein level but impaired C1-
INH function [7,8]. C4 is reduced in 98% of cases for
both HAE-1 and HAE-2, and nearly 100% of the time
during an attack [7].
HAE-nC1INH (previously referred to as type 3 HAE), is
much less prevalent than HAE-1 and HAE-2. The true
prevalence is not known as there are no reliable assays to
screen for this condition. In about 20% to 25% of identified
patients, causative mutations in the gene coding for the co-
agulation factor XII (F12) have been found (HAE-nC1INH-
FXII) whereas in the remaining patients no genetic cause
has been identified up to now (HAE-nC1INH-unknown)
[11-13]. The exact pathogenesis, however, including the
mode of action of the F12 gene mutations and the role of
estrogens is still unknown. The lack of laboratory and gen-
etic assays (with the exception of F12 gene mutations) to
diagnose HAE-nC1INH, has made the identification of
these patients more difficult than patients with HAE-1
or HAE-2. A recent international consensus group hasTable 1 Laboratory findings in hereditary angioedema
C4 C1-INHAntigen C1INH Function
HAE - 1 ↓ ↓ ↓
HAE - 2 ↓ Normal or ↑ ↓
HAE - nC1INH
-FXII mutation Normal Normal Normal
-UnknownCause Normal Normal Normal
References [9,10].published criteria to make the diagnosis of HAE-nC1INH
[13]. These included a history of recurrent angioedema in
the absence of concomitant hives or use of medication
known to cause angioedema; documented normal or near
normal C4, C1-INH antigen and function; and either a
F12gene mutation associated with the disease, or family
history of angioedema and documented lack of efficacy of
chronic high dose non-sedating antihistamine therapy [13].
Management of HAE can be divided into various ap-
proaches. The aim of treatment of acute attacks, also re-
ferred to as ‘on demand therapy’ is to minimize their
severity, including potentially fatal upper airway edema,
and associated impairment of Quality of Life (QoL). Short
term prophylaxis (STP) refers to treatment meant to
minimize the risk of attacks when avoidance of potential
and known triggers is not possible. Long term prophylaxis
(LTP) refers to ongoing treatment of HAE aimed at min-
imizing the overall number, frequency and/or severity of
attacks. The details of specific therapies for these treat-
ment approaches will be discussed in the sections that fol-
low. In addition to the evidence behind the proposed
recommendations, the clinical considerations for their im-
plementation will also be discussed. The United States
Preventive Services Task Force describes clinical consider-
ations as statements that can help clinicians by offering
practical information so they can tailor guideline recom-
mendations to individual patients [14]. This Clinical Con-
sideration section following each recommendation is
intended to help place the recommendation into a clinical
context.
Scope and purpose
The objective of this guideline is to provide graded recom-
mendations for the management of patients in Canada
with HAE-1, HAE-2 and HAE-nC1INH. This includes the
treatment of attacks, STP, LTP, and recommendations for
self-administration, individualized therapy, QoL, and com-
prehensive care.
The care of patients with HAE in Canada is neither
optimal nor uniform across the country. It lags behind
other countries where there are more organized models
for HAE management, and where additional therapeutic
options are licensed and available for use [15]. It is antic-
ipated that by providing this guideline to caregivers, pol-
icy makers, patients and their advocates, that there will
be an improved understanding of the current recom-
mendations regarding management of HAE and the fac-
tors that need to be considered when choosing therapies
and treatment plans for individual patients.
It is not the intent of this guideline to provide a detailed
description of the pathophysiology or nomenclature of
HAE which can be found elsewhere [13]. It is also not
intended to be prescriptive in its recommendations, but
rather to highlight issues that need to be considered when
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the importance of individualized care.
Intended audience
The primary target users of this guideline are healthcare
providers who are managing patients with HAE-1, HAE-2
and HAE-nC1INH. Other healthcare providers who may
use this guideline are emergency physicians, gastroenterol-
ogists, dentists and otolaryngologists, who will encounter
patients with HAE and need to be aware of this condition.
Hospital administrators, insurers and policy makers may
also find this guideline helpful.
Methods
Committee members and consensus conference
participants
The Canadian Hereditary Angioedema Guideline Commit-
tee is a working committee under the umbrella of the
Canadian Hereditary Angioedema Network (CHAEN)/
Réseau Canadien d'angioédème héréditaire (RCAH) http://
chaen-rcah.ca/. Members on this committee included
members from CHAEN/RCAH across Canada as well as
the President of the Canadian HAE Patient Organization –
Hereditary Angioedema (HAE) Canada/Angioédème
Héréditaire (AEH) Canada. The Canadian Hereditary
Angioedema Committee was responsible for defining the
scope and purpose of the guideline and choosing the inter-
national participants. International participants were se-
lected based on their contributions to the HAE literature,
relating to HAE and its management, and their ex-
pertise in priority areas for this guideline including
self-administration, individualized therapy, HRQoL, and
comprehensive care. Those identified experts were asked
to present a summary of the evidence related to these
areas to all conference participants.
Conference participants included the CHAEN/RCAH
Guideline Committee, international experts, all currently
registered members of CHAEN who were able to attend
the meeting, the President of HAE/AEH Canada and
their designates, President of the international HAE pa-
tient group HAEi, Hema-Quebec, and industry represen-
tatives. An invitation was extended to representatives of
the Provincial/Territorial Blood Coordinating offices.
Representatives from Industry, who manufacture prod-
ucts for the treatment of HAE, were also invited to pro-
vide information on their products if required during
the meeting. Only medical personnel and general man-
agers were invited but were not present during times
when decisions were made. Marketing representatives
were excluded.
Funding and support
Funding for the CHAEN/RCAH Guideline Conference was
done through the CHAEN/RCAH. This organizationreceived equal support from 3 companies, who manufac-
ture products for the treatment of hereditary angioedema
(CSL Behring, Shire, and ViroPharma - Viropharma was ac-
quired by Shire between the time of the guideline meeting
and publication of the Guideline). Requests to procure
funding from Provincial and National Government and
Blood Agencies were not successful. Funding was used to
support rental of the conference facilities, audio-taping, fa-
cilitation by an external facilitator, travel to the meeting,
accommodation, and foods for all participants except for
government agency representatives and patient represen-
tatives who were supported by their own agencies. No in-
dustry participants were funded by CHAEN/RCAH. No
participants at the meeting were compensated for their
time except for the Guideline meeting methodologist and
facilitator from the Centre of Effective Practice.
The guideline meeting process was aided by a method-
ologist and a guideline facilitator from the Centre for
Effective Practice and supported by HAE/AEH Canada.Conflict of interest
Details of potential conflicts of interest were elicited using
the standardized International Committee of Medical
Journal Editors Form for Disclosure of Potential Conflicts
of Interest (Additional file 1). COI forms were distributed
to attendees prior to their reviewing the manuscript, and
were mandatory for all contributing authors.Identifying the evidence
A systematic search of Ovid MEDLINE was conducted
by a librarian from the Centre for Effective Practice
(KLR) on October 10, 2013, in order to identify clinical
trials addressing long-and short-term prophylaxis and
treatment of acute attacks in patients of any age diag-
nosed with HAE-1, HAE-2, or HAE-nC1INH. Out-
comes of interest included frequency or severity of
attacks, symptom relief and QoL measures as reported
or measured by the affected subject or investigator.
Studies were limited to English language publications,
and there were no limits on the publication date of
study other than those imposed by the database (1946-
October week 1, 2013). After duplicates were removed,
416 results were found, the abstracts of which were
reviewed to determine if they met the inclusion criteria.
If unclear from the abstract whether the paper met
these criteria, the full-text document was reviewed. One
hundred and thirty two results were retrieved and
reviewed in full text, and from this, 11 relevant random-
ized control trials and 34 lower-quality comparative
studies without blinding or randomization were identi-
fied and included. No studies which met the inclusion
criteria were identified for HAE-nC1INH. The full
search strategy is available in Additional file 2.
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Key information from the included studies such as study
design, number of patients, outcome measures, side effects
and funding source was extracted into evidence tables for
each intervention (see Additional file 3). Evidence tables
were provided to the Committee Members and were avail-
able for reference at the meeting.
Criteria for determining Levels of Evidence and Strength
of Recommendation were adapted from the GRADE sys-
tem, [16-18] and the process was based primarily on the
Journal of Clinical Epidemiology’s 2011–2013 series of ar-
ticles describing the GRADE methodology. GRADE is
considered “outcome centric,” and traditionally recom-
mends a single rating for each outcome across the full
body of evidence. The method applied here involved
evaluating the quality of each study individually, and then
looking at the studies together to assign a Level of
Evidence based on the collection of studies.
Each identified randomized control trial was assessed by
two reviewers (KL-R, VP) for quality using the Cochrane
Risk of Bias Tool [19]. Any disagreements were resolved
by a third reviewer (SB). Randomized trials were initially
rated as High quality levels of evidence, with quality being
downgraded for evidence of bias on the Cochrane tool and
if there was evidence of inconsistency (Additional file 3:
Table S1). Non-randomized, non-blinded trials were con-
sidered to be Low quality evidence.
Multiple factors were considered when assigning the
Strength of Recommendation, including quality of evidence,
balance between desirable and undesirable effects, values
and preferences, and costs (Additional file 3: Table S2).
Additional file 3 describes additional detail how quality
was assessed and the criteria used to determine
the Strength of Recommendation. The quality ratings were
presented at the meeting during the discussion of draft rec-
ommendations. Additional files 4 and 5 list the HAE RCT
evidence tables and the lower quality comparison study evi-
dence respectively.
Recommendation development and approval
The Chair (SB) developed draft recommendations based
on the identified literature, and presented them to the
Committee Members who approved them in draft. In-
vited Committee Members were assigned specific topic
areas and were asked to review the evidence relevant to
their topic and present the body of evidence for consid-
eration at the Guideline meeting. After the summary
was presented, the Consensus Conference Participants
were provided an opportunity to discuss the literature.
Following this discussion, the draft recommendation was
presented and the group discussed the specific wording
of the recommendation before voting anonymously via
electronic voting to agree or disagree with the recommen-
dation, or abstain. If 80% consensus was not reached, therewas additional group discussion, the recommendation was
rephrased, and a new vote conducted. This process was
conducted a maximum of 3 times. If 80% consensus was
not reached, it was considered that the committee was un-
able to reach consensus.
Once the phrasing of a recommendation was approved
by the group, the proposed Level of Evidence was pre-
sented by the methodologist guideline facilitator (High,
Moderate, Low, Very Low, or Consensus). The Level of
Evidence was then discussed, revised if necessary, and
similarly voted on as outlined above.
The suggested Strength of Recommendation (Strong or
Weak) was then presented to the group. The methodologist
guideline facilitator proposed a Strength of Recommenda-
tion based on the Level of Evidence, the balance between
desirable and undesirable effects, values and preferences.
These factors were discussed amongst the group before vot-
ing to accept the proposed Strength of Recommendation.
All votes were recorded and presented in real time with the
recommendations. Table 2 is a summary of all the recom-
mendations, the level of evidence supporting each recom-
mendation, and the strength of each recommendation.
For each topic area, group discussions were captured
on audiotape, and used to inform the clinical consider-
ations for each recommendation.
To mitigate any real or perceived bias that may have influ-
enced the outcomes, industry representatives at the meeting
were asked to leave the room after the scientific presenta-
tions and were not present during any discussion either of
the data, wording of the recommendations, levels of evi-
dence, strength of recommendations, or the voting process.
Prior to the in-person meeting, the Committee Members
determined that open discussion amongst conference par-
ticipants regarding an approach to individualized therapy
would be beneficial. For this topic, small round table discus-
sions were facilitated prior to recommendation review and
voting, and additional clinical considerations were.
Guideline recommendations
Treatment of acute attacks of HAE types 1 and 2
Background
Acute attacks of HAE may be spontaneous or precipi-
tated by an external stimulus and range from mild to
life-threatening. The decision to treat an attack depends
on many variables and the severity of an attack cannot
always be predicted by its earliest manifestations. The
aim of treating acute attacks is to reduce the duration
and severity of an attack, to minimize the impact of an
attack on the functional ability of the patient, and reduce
morbidity and potential mortality.
Despite the increase in available beneficial therapies,
some therapies which have not been shown to be effect-
ive in trials continue to be used in acute attacks due to
either historical precedent or lack of awareness.
Table 2 Summary of recommendations
Recommendation Level of Evidence and Strength of
Recommendation
Treatment of Acute Angioedema Attacks
1. Effective therapy should be used to treat acute attacks of angioedema to reduce duration and severity of
attacks.
High, Strong
2. pdC1-INH is an effective therapy for the treatment of acute attacks. High, Strong
3. Icatibant is an effective therapy for the treatment of acute attacks. High, Strong
4. Ecallantide is an effective therapy for the treatment of acute attacks. High, Strong
5. rhC1-INH is an effective therapy for the treatment of acute attacks. High, Strong
6. Attenuated androgens should not be used to treat acute attacks. Low, Strong
7. Tranexamic acid should not be used to treat acute attacks. Low, Strong
8. Frozen plasma could be used for treatment of acute attacks if other recommended therapies are not
available.
Low, Strong
9. We recommend early treatment of attacks to reduce morbidity (Level of Evidence: Moderate) and
mortality (Level of Evidence: Expert Opinion).
Moderate, Strong/Expert Opinion,
Strong
10. All attacks of angioedema involving the upper airway are medical emergencies and must be treated
immediately. (Level of Evidence: Low) In addition, we recommend emergency department assessment.
(Level of Evidence: Expert Opinion).
Low/Expert Opinion, Strong
Acute Treatment of HAE with Normal C1-INH
11. There is insufficient evidence to make a recommendation for or against the use of HAE-specific
therapies in the treatment of acute attacks in patients with HAE with normal C1-INH.
Very Low / Insufficient Evidence
Short-Term Prophylaxis
12. Short-term prophylaxis should be considered prior to known patient-specific triggers and for any
medical, surgical or dental procedures.
Low, Strong
13. HAE-specific acute treatment should be available during and after any procedure. Low, Strong
Long-Term Prophylaxis In HAE 1 & 2
14. Long-term prophylaxis may be appropriate for some patients to reduce frequency, duration and
severity of attacks.
High, Strong
15. Attenuated androgens are effective for long-term prophylaxis in some patients. Moderate, Strong
16. Plasma-derived C1-INH is effective for long-term prophylaxis in some patients. High, Strong
17. Anti-fibrinolytics are effective for long-term prophylaxis in some patients. Moderate, Strong
18. It is not necessary to fail other long-term prophylaxis therapies before use of C1-INH for long-term
prophylaxis is considered.
Expert Opinion, Strong
19. There is insufficient evidence to make a recommendation for or against long-term prophylaxis for
patients with HAE with normal C1-INH.
Very Low/Insufficient Evidence
Self-Administration
20. All patients should be trained on self-administration of HAE-specific therapies if they are suitable
candidates. If patients cannot self-administer therapy, provisions should be made to ensure timely
access to all appropriate therapies.
Low, Strong
Approach to Individualized Therapy
21. The decision to start or stop long-term prophylaxis depends on multiple factors and should be made
by the patient and an HAE specialist.
Expert Opinion, Strong
Quality of Life
22. Health care providers should specifically address factors known to affect quality of life with HAE
patients. Management of HAE should aim to improve patients’ quality of life.
Low, Strong
Comprehensive Care
23. Comprehensive care should be available for all patients with HAE. Low, Strong
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strated improvement in duration and severity of acute
attacks of HAE types 1 and 2 [20-29]. The therapiesstudied were plasma derived C1-INH (pdC1-INH), re-
combinant human C1-INH (rhC1-INH), icatibant and
ecallantide. Table 3 lists the specific agents, their
Table 3 Therapies for HAE supported by high level of evidence
HAE specific
treatment
Product name and
company
Mechanism of
Action
Approved
Indications In
Canada
Dose Adverse Events
C1-INH
– Plasma
Berinert® (CSL) Replaces CI-INH Acute
treatment
20 IU/Kg intravenous Anaphylaxis/Thrombosis (rare);Transmission
of infectious agents (theoretical)
Cinryze® (Shire) Replaces CI-INH Long term
Prophylaxis
1000 IU q3-4 days
intravenous
Anaphylaxis/Thrombosis (rare);Transmission
of infectious agents (theoretical)
– Recombinant Rhucin® (Pharming) Replaces CI-INH Not licensed 50 U/Kg Intravenous Anaphylaxis (rare)
Ecallantide Kalbitor® (Dyax) Inhibits plasma
kallikrein
Not licensed 30 mg subcutaneous
injection
Anaphylaxis (uncommon)
Icatibant Firazyr® (Shire) Blocks bradykinin 2
receptor
Acute
treatment
30 mg subcutaneous
injection
Pain, swelling, pruritis at injection site
(common)
Exacerbation of coronary artery disease
(theoretical)
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Canada, the recommended dosages, and important
potential adverse reactions. The quality of individual
studies is described under the drug-specific recom-
mendations which follow. Based on the rating of
each study using the Cochrane Risk of Bias Tool
(see Additional file 4), as well as the overall consistent
effect of therapy on the relevant outcomes (reduction of
duration and severity of acute attacks), and effect size, this
body of evidence determined by the conference partici-
pants to be of High quality.
Based on the Level of Evidence, the potential severity
of the outcomes and the low risk of adverse effects, the
panel voted for a Strong Recommendation in favour of
the use of effective therapies in the treatment of acute
attacks.
Recommendation 1
Effective therapy should be used to treat acute
attacks of angioedema to reduce duration and
severity of attacks.
Level of Evidence: High (96% Agree, 4% Disagree)
Strength of Recommendation: Strong (100% Agree)
Clinical considerations
The panel emphasized the importance of changing
practice towards the use of effective therapies based
on evidence based data, and specifically not using
therapies which were not supported by evidence, such
as antihistamines, corticosteroids and epinephrine
which are directed at treating histamine mediated
angioedema.
Recommendation 2
pdC1-INH is an effective therapy for the treatment
of acute attacks.
Level of Evidence: High (100% Agree)
Strength of Recommendation: Strong (100% Agree)Clinical considerations
The pdC1-INH is a human blood product. Treatment with
pdC1-INHreplaces the deficient protein in patients with
HAE-1 and HAE-2.Berinert® (CSL Canada) is the only li-
censed product in Canada for the treatment of acute attacks
of HAE-1 and HAE-2. It has been licensed since 2010, and
is available throughout Canada, through Canadian Blood
Services or Hema-Quebec. It can be used to treat all attacks
of HAE-1 and HAE-2 in adults and children. The recom-
mended dosage is 20 U/kg administered intravenously ei-
ther by healthcare professionals or by patients and their
caregivers who have been trained in its administration. It
has been shown to effectively treat acute attacks in pediatric
and adult patients with HAE-1 and HAE-2 [22].
Although not currently licensed in Canada for the
treatment of acute attacks, Cinryze® (Shire) is licensed in
Europe for treatment of acute attacks in adolescent and
adult patients with HAE-1 and HAE-2at a dose of 1000
units intravenously initially and another 1000 units if no
response. It has been shown to reduce the median time
to onset of unequivocal relief of symptoms compared to
placebo group [29].
The dose derived for treatment of acute attacks comes
from clinical trials. There have been no head to head trials
comparing products so it cannot be concluded that differ-
ent doses of different products were equally effective.
There is some evidence that efficacy is dose dependant,
but this has not been confirmed with rigorous dose find-
ing trials [30]. The pdC1-INH products are safe and well
tolerated when used as indicated with no documented
transmission of infectious agents.
Recommendation 3
Icatibant is an effective therapy for the treatment
of acute attacks.
Level of Evidence: High (97% Agree, 3% Disagree)
Strength of Recommendation: Strong (96% Agree/
4% Disagree)
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Bradykinin is a key mediator in inducing angioedema
through activation of the bradykinin B2 receptor [6]. Icati-
bant is a synthetic 10-amino acid peptide and acts as a
selective bradykinin B2 receptor antagonist. It is adminis-
tered as a single 30 mg subcutaneous injection. It has been
shown to effectively treat acute attacks in adult patients
with HAE-1 and HAE-2 [20,25]. Icatibant is licensed in
Europe and the USA for self-administration for the treat-
ment of HAE attacks. (Addendum: Icatibant was licensed
by Health Canada July 16, 2014). It is generally well-
tolerated, although 90% of patients experience transient
local pain, swelling, and erythema at the injection site.
Recommendation 4
Ecallantide is an effective therapy for the treatment
of acute attacks.
Level of Evidence: High (94% Agree, 6% Disagree)
Strength of Recommendation: Strong (94% Agree,
6% Disagree)
Clinical considerations
Plasma kallikrein generates bradykinin through cleavage
of high-molecular-weight kininogen [6,31,32]. Ecallantide
is a 60-amino acid recombinant protein that acts as an in-
hibitor of kallikrein. It is administered as three 10 mg sub-
cutaneous injections for a total dose of 30 mg. It has been
shown to effectively treat acute attacks in adolescent and
adult patients with HAE-1 and HAE-2 [26]. Martinez-
Saguer et al. [33] ecallantide (is not currently licensed in
Canada but access can be requested through) the Special
Access Program of Health Canada. Hypersensitivity and
sometimes anaphylactic-type reactions have been de-
scribed with this agent in 5% or administrations, of which
approximately 50% were possible anaphylactic reactions.
Subcutaneous administration is associated with fewer
of these episodes (1.6%), but is still a concern [32]. In the
USA, ecallantide is approved for treatment of acute at-
tacks, but must only be administered by healthcare profes-
sionals who are trained and are prepared to treat adverse
reactions.
Recommendation 5
rhC1-INH is an effective therapy for the treatment
of acute attacks.
Level of Evidence: High (100% Agree)
Strength of Recommendation: Strong (97% Agree,
3% Abstain)
Clinical considerations
The rhC1-INH (conestat-alpha) is generated in the
mammary glands of transgenic rabbits and is identical to
pdC1-INH except for the degree of protein glycosylation
[34]. This difference in glycosylation results in shorterplasma mean half-life of the recombinant product
[33,35], however the effect this has on physiologic activ-
ity is not known [30]. It has been shown to effectively
treat acute attacks in adult patients with HAE-1 and
HAE-2 [28]. It is administered intravenously at a dose of
50 U/kg in people up to 84 Kg and at a dose of 4200 U
for people above 84 Kg. Because of an isolated anaphyl-
actic reaction after administration of rhC1-INH to a
rabbit allergic person, those with anti-rabbit IgE should
be excluded before prescribing. It is not currently li-
censed in Canada but access can be requested through
the Special Access Program of Health Canada.
Recommendation 6
Attenuated androgens should not be used to treat
acute attacks.
Level of Evidence: Low (97% Agree, 3% Abstain)
Strength of Recommendation: Strong (100% Agree)
Recommendation 7
Tranexamic acid should not be used to treat acute
attacks.
Level of Evidence: Low (93% Agree, 7% Disagree)
Strength of Recommendation: Strong (83% Agree,
10% Disagree, 7% Abstain)
Clinical considerations
Attenuated androgens such as the 17 α-alkylated ana-
bolic androgen danazol and anti-fibrinolytic drugs such
as tranexamic acid have not been shown to be effica-
cious in the treatment of acute attacks of HAE-1 and
HAE-2. Given the lack of evidence for these agents in
the acute treatment of HAE, the Committee strongly
agreed that they should not be used for the treatment of
acute HAE attacks as other agents with documented ef-
ficacy are available in Canada.
Recommendation 8
Frozen plasma could be used for treatment of acute
attacks if other recommended therapies are not
available.
Level of Evidence: Low (96% Agree, 4% Abstain)
Strength of Recommendation: Strong (100% Agree)
Clinical considerations
Frozen plasma (FP) is a blood product which contains C1-
INH in association with other plasma proteins. Frozen
plasma (FP) is not as safe as solvent detergent plasma
(SDP) with respect to pathogen inactivation, and the level
of evidence that frozen plasma is effective in the treatment
of acute attacks of HAE −1 and HAE-2 is low. It also con-
tains potential substrates for the generation of additional
bradykinin and in theory could worsen attacks of angio-
edema. Also, not all blood banks in Canada stock FP and
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Hence, there may be a significant delay in getting FP and/
or SDP in a timely manner - in some cases up to 24 hours.
Therefore, it was strongly felt by the Committee that frozen
plasma products, although potentially beneficial, should
only be used if other recommended therapies are not avail-
able and that every effort should be made to ensure timely
and appropriate therapy for acute attacks [36,37].
Recommendation 9
We recommend early treatment of attacks to
reduce morbidity (Level of Evidence: Moderate)
and mortality (Level of Evidence: Expert Opinion).
Level of Evidence: Moderate (92% Agree, 8% Disagree)
Strength of Recommendation: Expert Opinion/
Strong (92% Agree, 4% Disagree, 4% Abstain)
Clinical considerations
Early treatment likely leads to more rapid symptom reso-
lution. Observational studies have suggested that early
treatment can be efficacious in reducing the duration of an
attacking some patients [38-42]. Therefore, despite the ab-
sence of a high level of evidence, expert opinion was strong
endorsing early treatment in an attempt to reduce morbid-
ity and likely mortality. Because of the potential barriers in
accessing therapy in a timely manner, patients should be
trained on how to self-administer therapies appropriate for
the treatment of acute attacks of HAE. If patients are not
able to self-administer their own therapy, efforts should be
made to ensure that this therapy is made available to them
without a significant delay (see Recommendation #21).
Recommendation 10
All attacks of angioedema involving the upper
airway are medical emergencies and must be
treated immediately. (Level of Evidence: Low) In
addition, we recommend emergency department
assessment. (Level of Evidence: Expert Opinion).
Level of Evidence: Low (96% Agree, 4% Disagree)
Strength of Recommendation: Expert Opinion/
Strong (100% Agree)
Clinical considerations
Attacks of HAE are unpredictable and potentially life-
threatening. Mortality due to laryngeal angioedema is
well recognized [3]. All attacks of laryngeal angioedema
should be considered medical emergencies, and therapies
that have been shown to be effective in the treatment of
HAE should be readily available and given immediately. It
is also recommended that all patients with laryngeal
edema, even following self-therapy, be assessed in the
emergency department in the event that the angioedema
does not respond to therapy, and expertise in airway man-
agement is required [43].Treatment of acute attacks of HAE with normal C1 INH
function
Background
HAE-nC1INH is a rare disease that can be a challenge to
diagnose with certainty as was discussed above. It has been
suggested, without confirmatory evidence that bradykinin
may play a role in the pathogenesis of this disease which
has led to speculation that therapies used for HAE-1 and
HAE-2 may be beneficial [13]. There is also indirect evi-
dence that anti-histamine therapy is not effective in this pa-
tient group [44]. Owing to the difficulty in identifying this
subset of patients with HAE, and that there have been nei-
ther significant case series nor controlled clinical trials with
respect to therapeutic intervention for acute attacks, we
cannot recommend specific therapeutic interventions as
this time.
Recommendation 11
There is insufficient evidence to make a
recommendation for or against the use of HAE-
specific therapies in the treatment of acute attacks
in patients with HAE with normal C1-INH.
Level of Evidence: Very Low (96% Agree, 4% Disagree)
Strength of Recommendation: Insufficient
Evidence (N/A)
Clinical considerations
The committee felt that there was insufficient evidence
to make a specific recommendation regarding the use of
therapies that have been shown to be efficacious for the
acute treatment of HAE-1 and HAE-2 in patients with
HAE-nC1INH.
However, in spite of this, if patients meet the clinical pro-
file of HAE-nC1INH, a trial of HAE specific therapy could
still be considered with the understanding that there is a
very low level of evidence to support this and some reports
demonstrate lack of efficacy for use of either pdC1INH or
icatibant [45-48]. This may not be surprising given that
there are neither abnormalities in C1-INH level or func-
tion, nor any confirmatory evidence if a role for bradykinin.
Short-term prophylaxis
Background
STP refers to the practice of treating patients to reduce
the risk of associated and consequent morbidity and
mortality during a period of time when there may be an
increased risk of having an attack of angioedema.
It is well recognized that physical trauma, as can occur
during medical and dental procedures, can induce epi-
sodes of angioedema [49,50]. Upper airway manipula-
tion, including during dental surgery and intubation, is
at particularly high risk due to its association with upper
airway swelling. However, even minor procedures can
precipitate angioedema and the ability to predict when
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can occur anywhere from hours to several days after a
procedure [49].
It is also suspected that other causes, such as emo-
tional stressors can precipitate attacks. Individual pa-
tients may also be aware of specific triggers that have
been known to trigger their attacks.
Despite these observations, there is a lack of controlled
clinical trials in this area, and most data come from
retrospective reviews and surveys [49,51-53].
Recommendation 12
Short-term prophylaxis should be considered prior
to known patient-specific triggers and for any
medical, surgical or dental procedures.
Level of Evidence: Low(96% Agree, 4% Disagree)
Strength of Recommendation: Strong (93% Agree,
7% Disagree)Recommendation 13
HAE-specific acute treatment should be available
during and after any procedure.
Level of Evidence: Low(92% Agree, 4% Disagree, 4%
Abstain)
Strength of Recommendation: Strong (100% Agree)Clinical considerations
There was extensive discussion as to when STP should
be used and consideration was given to the development
of a list of high and low risk procedures in this context.
However, there is lack of data regarding the specific risk
associated with each of a wide range of medical and den-
tal procedures; it was felt that STP should be considered
for all medical, surgical and dental procedures. One
study assessed the risk of angioedema following surgery
without prior pre-procedural prophylaxis as 5 – 30%, irre-
spective of type and extent of surgery [53]. Based on this,
and our inability to link the risk of an attack to a specific
procedure [49,53]; it was felt that STP should at least be
considered for all procedures as well as known patient-
specific triggers. This recommendation was intended to
remain broad in its scope as the risk of appropriate STP
would likely be minimal compared to any real or perceived
risk of not using STP when felt necessary. If the decision
is made not to administer STP, all patients should have
two acute treatment doses of appropriate therapy immedi-
ately available as per Recommendation 13. What is not
known from the current data is how many patients have
been denied, or have chosen not to pursue necessary pro-
cedures due to perceived risks, or not being offered STP.
Ensuring access to STP may help mitigate the risk associ-
ated with procedures and enable patients to seek and re-
ceive the care they need [54].In the absence of rigorous data on specific dosing,
pre-procedural prophylaxis with pdC1-INHconcentrate
is recommended however there have not been controlled
dose finding studies. Response however does appear to
be dose related. In one study patients had about a 30%
risk with no prophylaxis, 15% risk with 500 units of
pdC1-INH which was reduced to about 5% risk at 1000
units [49]. Furthermore, given that breakthrough attacks
have occurred even with prophylactic pdC1-INH con-
centrates at 1,000 units, at least one additional treatment
for acute attacks should be available. In Canada, pdC1-
INHBerinert®is approved by Health Canada for acute
treatment and pdC1-INH Cinryze is approved by Health
Canada for long-term prophylaxis. In Europe, Cinryze is
licensed to be given 1000 units within 24 hours of the
procedure, or Berinert1000 units within 6 hours of an
anticipated procedure.
Attenuated androgens may be considered for STP when
surgery-related risk is considered low and other HAE-
specific acute treatments are not immediately available. If
androgens are chosen for STP, Danazol can be considered
starting 5 days before the anticipated procedure or trigger
and continuing 2–3 days after the anticipated trigger
(Danazol 2.5 to 10 mg/kg/day, maximum 600 mg/day) [9].
Disadvantages with androgen therapy include perceived
inferior efficacy to pdC1-INH concentrate and side effects
such as emotional irritation and lability, menstrual dis-
turbance, and vaginal dryness which can occur with short
term use. Attenuated androgens areal so not suitable in
pregnancy nor during breast feeding, and a pregnancy test
should be considered before initiation of therapy with an-
drogens. Recurrent short-term uses may be associated
with similar effects seen with long-term androgen use as
discussed below.
Anti-fibrinolytic agents such as tranexamic acid have
been used for STP with suggested dosages of 25 mg/kg
2–3 times daily to a maximum of 3–6 g per day, 5 days
before and 2–5 days after the procedure or anticipated
trigger. The efficacy for prevention of attacks, however,
is unknown and this agent should only be used if other
therapies are not available.Long-term prophylaxis in HAE types 1 and 2
Background
LTP refers to the use of ongoing regular treatment to
prevent attacks of HAE when on demand treatment
does not sufficiently meet patient treatment require-
ments as discussed below in the Approach to Individual-
ized Therapy section. Prophylactic therapy may be
considered for patients with recurrent episodes of angio-
edema to reduce the frequency, duration and severity of
attacks. The specifics of when to consider and when to
initiate LTP are discussed below.
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Long-term prophylaxis may be appropriate for
some patients to reduce frequency, duration and
severity of attacks.
Level of Evidence: High (100% Agree)
Strength of Recommendation: Strong (100%)
Clinical considerations
The aim of LTP is to reduce the frequency and/or severity
of attacks of HAE and minimize the impact of HAE on
their QoL so as to enable patients to live normal lives.
Some patients may be candidates for long-term therapy
and the benefits and risks associated with such treatments
should be explored to optimize patient care. It is important
to remember that no prophylactic regimen has been associ-
ated with the complete elimination of angioedema. There-
fore, despite being on prophylaxis, all patients should be
equipped to treat acute attacks in a manner consistent with
Recommendation #1 and an acute treatment plan should
be agreed between patient and physician.
Recommendation 15
Attenuated androgens are effective for long-term
prophylaxis in some patients.
Level of Evidence: Moderate (92% Agree, 4%
Disagree, 4% Abstain)
Strength of Recommendation: Strong (90% Agree,
6% Disagree, 4% Abstain)
Clinical considerations
Controlled trials and observational studies have demon-
strated that treatment with 17-alpha-alkylated anabolic
androgens, such as danazol, reduces the frequency and se-
verity of HAE attacks [55-60]. Although one of the trials
was a randomized controlled trial the level of evidence for
the trial was not considered High as there were insuffi-
cient details on funding, sequence generation, and out-
come reporting [55]. Historically, many patients have been
controlled with androgen therapy and their use in some
patients may be acceptable provided that the lowest effect-
ive dose is used to achieve efficacy and minimize adverse
effects. Expert opinion suggests the optimal dose for dana-
zol, to minimize adverse effects, is ≤200 mg/day [9].
Androgens can affect serum lipid levels, can be hep-
atotoxic resulting in hepatitis and have been associated
with hepatocellular adenoma and, in very rare cases,
carcinoma [58,61,62]. It is recommended that all pa-
tients on androgen therapy be monitored for hyperten-
sion and have a complete blood count, liver enzymes,
urinalysis, serum alpha-fetoprotein, creatine phosphoki-
nase and lipid profile performed every 6 months, and an
annual liver ultrasound [15].
Virilising effects of androgen therapy can occur and in-
clude menstrual irregularities, masculinization, irreversiblevoice alteration, and hirsutism. Psychological side effects in-
clude emotional irritability and lability, aggressive behaviour
and depression. Androgens are associated with interactions
with several medications. They are contraindicated in preg-
nancy and during lactation, before puberty, and in patients
with androgen-dependent malignancy and hepatitis [61,62].
Patients need to be made aware of these side effects
when considering and while on androgen therapy and
physicians should carefully consider the risks and benefits
for the particular patient.
Recommendation 16
Plasma-derived C1-INH is effective for long-term
prophylaxis in some patients.
Level of Evidence: High (100% Agree)
Strength of Recommendation: Strong (100% Agree)
Clinical considerations
Controlled clinical trials have demonstrated that pdC1-
INH used for prophylaxis in HAE-1 and HAE-2 reduces
the number, duration and severity of attacks of angio-
edema [27,29]. Currently, Cinryze® (Shire) is the only ap-
proved pdC1INH product for HAE prophylaxis in
Canada. However, this product has not yet been distrib-
uted in Canada. The dose of pdC1INH studied was 1000
U once or twice weekly (usually every 3–4 days). No dose
finding studies have been done and at 1000 units twice
a week the attacks are reduced by only 50%.
Side effects reported in trials with pdC1-INH are min-
imal. In the trial of Cinryze® for LTP, 21 of 24 subjects
(88%) had one or more adverse events, however only three
adverse events (pruritus and rash, light-headedness, and
fever) were classified as possibly related to the study drug.
Two patients in that study demonstrated an increase in the
number of attacks of HAE. A paper based on the FDA
registry of drug related adverse events, reported 10 cases of
severe thrombosis related to the use of Cinryze® in three
years between 2008 and 2011 [63]. The reason for these
thrombotic events has not been further elucidated. It has
been assumed to be related to the use of central lines. How-
ever, the use of these should also be avoided due to the as-
sociated risk of serious infection [63,64].
On-going monitoring of a patients response to therapy is
recommended. In addition, as intravenous therapy requires
ongoing venous access follow-up should ensure proper
technique is used to maximize the health of the veins.
Recommendation 17
Anti-fibrinolytics are effective for long-term
prophylaxis in some patients.
Level of Evidence: Moderate (96% Agree, 4%
Disagree)
Strength of Recommendation: Strong (86% Agree,
14% Disagree)
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The benefit of the anti-fibrinolytic agent tranexamic
acid was demonstrated in a randomized placebo con-
trolled trial with 18 subjects aged 12 years and over-
taking 1 g of tranexamic acid three times a day [65],
and a double-blind crossover study of epsilon amino-
caproic acid in 9 patients aged 7 to 40 years resulting
in these agents being given a moderate level of evi-
dence [66]. These data suggested that anti-fibrinolytic
agents could be useful for LTP for HAE-1 and HAE-2.
However, their role in current LTP was felt to be jus-
tified only in some patient groups due to the lack of
efficacy and the potential side effects at the dosage
studied. Although not specifically studied in paediat-
ric patients, it was felt, due to the concern of using
attenuated androgens in this patient demographic,
that anti-fibrinolytic agents could be considered. The
recommended dosage for tranexamic acid is 30–50 mg/kg
daily divided in 2 or 3 doses to a maximum of 6 g per day.
Recommendation 18
It is not necessary to fail other long-term
prophylaxis therapies before use of pdC1-INH for
long-term prophylaxis is considered.
Level of Evidence: Expert Opinion (100% Agree)
Strength of Recommendation: Strong (100% Agree)Clinical considerations
The elements to consider when deciding to start
prophylaxis are discussed below, in the approach to
individualized therapy section. However, there is no
recommended order or hierarchy for which therapies
should be chosen for LTP. This should be based on
the efficacy of the therapy, its side effects and safety,
and the patient’s preference. The participants were
unanimous in their recommendation that should a pa-
tient require long-term prophylaxis they can be
started on prophylactic pdC1-INH without need to be
tried on other prophylactic therapies first.Long-term prophylaxis in HAE with normal C1-INH
function
Background
Patients with HAE-nC1INH share similar clinical char-
acteristics with HAE-1 and HAE-2 patients, including
the risk of random unpredictable attacks of debilitating
and potentially life threatening angioedema [44]. These
similarities have led to speculation that treatments used
for LTP for HAE-1 and HAE-2 may be beneficial for pa-
tients with HAE-nC1-INH; however, due to the lack of
data a recommendation for this intervention could not
be made.Recommendation 19
There is insufficient evidence to make a
recommendation for or against long-term prophylaxis
for patients with HAE with normal C1-INH.
Level of Evidence: Very Low (100% Agree)
Strength of Recommendation: Insufficient
Evidence (N/A)
Clinical considerations
The absence of good evidence in the LTP of HAE with
nC1-INHpatients makes it difficult to make specific rec-
ommendations regarding treatment. Patients should
avoid known triggers of angioedema such as exogenous
estrogen and angiotensin converting enzyme (ACE) in-
hibitors. There is some evidence that progesterone,
anti-fibrinolytics and attenuated androgens may be effi-
cacious in patients with HAE-nC1INH [12]. However,
the data were of low quality and uniform recommenda-
tions could not be made regarding their use. The com-
mittee felt strongly that more data are needed in this
area and appropriate trials should be done to help guide
future treatment recommendations.
Self-administration
Background
Self-administration refers to the treatment of patients
outside of a health care facility either by the patient’s
themselves or by a trained caregiver. The recognition
and support of self-administration as treatment for HAE
go back to the first international consensus document
on HAE in 2003 and has been repeatedly recommended
in subsequent consensus statements and guidelines
[9,15,67]. It has been shown to be a safe and convenient
option for patients, allows for early treatment, and may
reduce the overall treatment costs of this group when
compared to hospital-based therapy [68]. However, des-
pite the demonstrated benefits of self-administration in
terms of efficacy and improved QoL, an online survey
done in the USA revealed that only 8.1% of treating phy-
sicians had patients who self-treated and only 3.5% re-
ceived home healthcare assisted administration [69,70].
Although specific data in Canada is lacking, there is little
reason to think it would differ much from these findings.
Self-administration of blood products for rare blood disor-
ders is not without precedent and has been the corner-
stone of effective therapy for hemophilia for more than
three decades in Canada [71].
Treatment is more efficacious when attacks are treated
early [72]. Evidence has shown that the earlier an attack
is treated the sooner it resolves [26,42,73,74]. The ability
to treat an attack early depends on reducing the number
of steps required between recognition of an attack that
requires treatment and implementation of effective treat-
ment. Obligating patients to travel to a health care
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effective when administered at home, or outside of a
healthcare facility, adds to the delay in receiving treat-
ment, may result in many attacks not being treated.
Patients may also face difficulties in accessing treatment
if local healthcare facilities are unfamiliar with this con-
dition. The World Allergy Organization’s global guide-
line emphasizes that all therapies should be available to
all HAE patients worldwide and that home- and self-
administration are preferred because they reduce morbidity,
absenteeism, cost, disease burden and potentially mortality,
as well as improveQoL [15,75].
Carrying a personal supply of pdC1-INH by patients
has been shown to reduce the time spent waiting
for treatment [5]. Additionally, patients who self-
administered or had on-demand therapy have been
shown to have reduced severity and duration of at-
tacks, and an improved QoL.
Recommendation 20
All patients should be trained on self-administration
of HAE-specific therapies if they are suitable
candidates. If patients cannot self-administer
therapy, provisions should be made to ensure timely
access to all appropriate therapies.
Level of Evidence: Low (100% Agree)
Strength of Recommendation: Strong (100%)
Clinical considerations
Although the level of evidence was low for the recommen-
dation that all patients should be trained on self-
administration of HAE-specific therapies if they are suit-
able candidates, it was considered a strong recommenda-
tion unanimously. This is consistent with prior consensus
statements and guidelines [9,15,76]. The importance of
early therapy should not be underestimated, and barriers
that affect its implementation should be removed. Cur-
rently in Canada, pdC1INH is licensed for on demand
therapy (Berinert®) and for routine prophylaxis (Cinryze®).
Because pdC1INH is a blood product and dispensed by
blood banks in Canada, blood banks should adapt uniform
operating procedures to enable access to pdC1INH by all
suitable candidates and ensure uniform care for all pa-
tients regardless of location. The Canada Health Act is
intended to guarantee equal access to health services and
health care. Geographic disparities in care are known to
exist. Self-administration of therapy in HAE will remove
these disparities. Although, pdC1INH is an intravenous
product and requires special considerations including
product tracking and patient training, the use of intraven-
ous blood products for self-administration is not unique.
Hemophilia self-administration programs, which are simi-
lar, have been widely implemented across Canada and have
been shown to be effective [71,77].Treatments that do not require intravenous access for
either acute treatment or prophylaxis would simplify self-
administered treatment. Ecallantide and icatibant are effi-
cacious subcutaneous therapies which are administered
for the treatment of acute attacks as discussed above. Ecal-
lantide is not licensed in Canada but may be accessed
through the special access program. Ecallantide should
usually be administered only by a healthcare practitioner
with experience and facilities to treat anaphylactic reac-
tions which occur in 3-8% of patients. Clinical trials are
also being conducted evaluating the use of subcutaneous
C1INH for LTP therapy [78,79].
Although not all patients will be suitable candidates for
self-administered therapy, the option should be considered
in the overall care plan of HAE patients. If patients are con-
sidered appropriate, and willing to learn self-administered
therapy, they should agree to specific criteria as outlined in
previously published international home-therapy guidelines
[80,81]. With self-administered therapy, patients need to be
regularly monitored to ensure appropriate control of their
symptoms, compliance and competency. This is discussed
further in the section on Individualized therapy.
Approach to individualized therapy
Background
HAE is a dynamic chronic disease and attacks of angio-
edema can vary in frequency and severity over the pa-
tient’s lifetime. This variability makes it important for
patients to be evaluated regularly to ensure that therapy
is appropriate and is being used correctly, and that side
effects of therapies are being minimized. A recently pub-
lished document outlines an approach to monitoring at-
tack frequency and severity [76].
Perhaps one of the most challenging areas in patient
treatment is deciding when to start or stop LTP therapy.
Although guidelines exist on which agents to use when
starting LTP, there is no evidence comparing the use of
LTP to acute on-demand therapy regarding benefit and
risk. In the absence of such evidence, given the clinical im-
portance of this therapeutic approach, the committee
attempted to determine which variables should be consid-
ered when trying to decide when to start or stop LTP.
Recommendation 21
The decision to start or stop long-term prophylaxis
depends on multiple factors and should be made by
the patient and an HAE specialist.
Level of Evidence: Expert Opinion (100% Agree)
Strength of Recommendation: Strong (97% Agree,
3% Disagree)
Clinical considerations
LTP should be considered when on-demand therapy
does not allow HAE patients to lead healthy and
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factors that should be considered when deciding to start
LTP. It was generally agreed that the key considerations
in making the decision included the efficacy of on-
demand therapy to control the severity and frequency of
attacks. Although in the past some consensus docu-
ments have tried to define the number and severity of
attacks as a reference point to consider when to start
LTP [10], there was significant concern about the arbi-
trary nature by which this would be defined. This ap-
proach might lead to denying LTP to patients whose QoL
is impacted, yet not meeting a specifically defined fre-
quency of attacks. It was felt that, although the frequency
of attacks is important, it is only one among many factors
including severity of previous attacks, how readily patients
can access emergency treatment, and their ability to ad-
minister on demand therapy, which should also be
considered.
Although the aim of LTP is to reduce the number and
severity of attacks, it does not eliminate the risk com-
pletely. Patients must be aware that starting LTP does not
mean that they will no longer have attacks and that those
attacks can still be fatal. All patients must have a plan to
treat attacks on demand despite being on LTP therapy. All
patients must be monitored to ensure that LTP is effica-
cious and that side effects are being recorded [76].
When starting LTP it is important to understand and
emphasize that LTP is not necessarily a lifelong therapy
and that treatment needs ongoing re-evaluation. It may
be helpful to try to define what the expectations are as
objectively as possible when starting LTP. Part of the
monitoring process should be to examine these goals
and ensure they are being met.
The decision to stop LTP also generated significant dis-
cussion. All participants felt LTP with androgens should
be stopped immediately if a patient became pregnant, was
breast feeding or if the patient was less than Tanner stage
5 development. Other factors that may lead to the consid-
eration of stopping LTP is ongoing stable control with
LTP therapy with no evidence of breakthrough attacks of
angioedema. If the decision to stop LTP is made, all pa-
tients must ensure that they have access to the administra-
tion of appropriate on-demand therapy of acute attacks as
is consistent with Recommendation #20. All members of
the patients comprehensive care team should be aware of
the plan to stop LTP in case complications arise.
When stopping LTP with attenuated androgens or
anti-fibrinolytics, the majority of participants agreed that
a gradual taper is recommended, if the patient is not
pregnant, while monitoring the frequency of and the im-
pact on the patient’s QoL. When stopping LTP with
pdC1-INH it was felt it could either be stopped abruptly
or the frequency of administration decreased, while
monitoring the patient’s response.The committee was unanimous that the decision to start
or stop LTP should be made jointly by the patient and an
HAE specialist. The patient needs to be informed of the
risks and benefits of all therapies, as discussed in the rele-
vant sections above, to enable making an informed deci-
sion. Particular attention is needed when attenuated
androgens are being considered for LTP in special popula-
tions such as women of childbearing age and children.
Additionally, long-term effects on vein health need to be
considered when considering repeated IV infusions.
Quality of life
Background
The Constitution of the World Health Organization
(WHO) defines health as “A state of complete physical,
mental, and social well-being not merely the absence of
disease.” It follows that the measurement of health and
the effects of health care must include not only changes
in the frequency and severity of diseases but also an esti-
mation of wellbeing and HRQoL. The impact of HAE on
a person’s HRQoL can be considerable. A survey done
in the USA in 2004 revealed that 85% of patients were
afraid of sudden closure of their airway, 75% experienced
intolerable pain and 53% were concerned about trans-
mitting HAE to their offspring [82]. A recent study of
457 HAE patients from the USA reported significantly
poorer health-related QoL versus population norms,
based on the SF-12 Physical Component Summary and
Mental Component Summary [83]. Productivity was also
markedly impaired in all Work Productivity and Activity
Impairment-General Health categories, including 34%
overall work impairment. Because of their most recent
HAE attack, workers lost a mean of 3.3 days; students
lost a mean of 1.9 days. In a Swedish registry of HAE pa-
tients missed days from work and school were docu-
mented [84]. In a multicenter European Study
absenteeism from work and school as well as marked
loss in productivity with the most recent attack and in
between attacks were recognized [85].
The Burden of Illness Study in Europe (Denmark,
Germany, Spain) have shown that HAE had a high im-
pact on daily activities during attacks and that HAE also
impacted patients’ daily activities between attacks
[73,85,86]. In this study patients also reported substan-
tial anxiety about future attacks, traveling, and passing
HAE to their children [82]. Based on Hospital Anxiety
and Depression Scale scores, 38 and 14% had clinically
meaningful anxiety and depression, respectively [73].
Moreover, 51% (n = 84) indicated that HAE had hin-
dered their career/educational advancement [85].
In Sweden and France, attack frequency was shown to
have a negative effect on HRQoL as measured by EQ5D
today [84] or SF-36 [87]. Attack severity was shown to
be related with absenteeism [84,85].
Table 4 Requirements for comprehensive care in the
management of hereditary angioedema patients
Best Clinical Treatment outcomes including:
a. A comprehensive care team made up of nurse coordinator,
clinician, social worker, data manager, pain management
specialist, genetic counsellor, and administrative support;
b. Access to specialized diagnostic testing;
c. Access to home treatment;
d. A networked Patient Information System to facilitate product
recalls - collect data on therapy outcome measures and safety,
and facilitate participation in clinical trials
e. Access to clinical advances as they become available;
f. Access to 24 hour support;
g. Access to up-to-date standards of care, including standardized
wallet cards;
h. Tracking and intermittent audit of quality outcomes including
beneficial and adverse outcomes through secure, comprehensive
and networked data management.
Education of patients and staff regarding:
a. Responsible Self/Family Care (home care model) with home and
self-infusion/administration instruction and support;
b. Developments in the cause, diagnosis, treatment, outcomes, and
prognosis of HAE
c. Changes in the administrative management of the clinic
An environment conducive to research including:
a. Access to and support for clinical trials of new treatments;
b. Access to and support for translational research in diagnosis and
prognosis;
c. Access to and support for psychosocial research such as quality of
life studies.
An advisory or oversight board with patient group representation
for each clinic
Reference [9].
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between attacks and on absenteeism during attacks
[73,84,85]. In aSpanish study assessing the development
of a disease-specific QoL questionnaire for adult patients
with hereditary angioedema due to C1 inhibitor defi-
ciency, the factors cited most often by both experts and
patients as affecting their QoL included potentially life-
threatening attacks; the adverse side effects of medica-
tion (in several cases associated with chronic treatment);
the unavailability of acute specific treatment at several
health care centres; hereditary transmission; the lack of a
known trigger which could be avoided; and the fact that
it is a rare disease about which health care professionals
know very little. The authors particularly noted that pa-
tients and experts may not agree on what are the most
relevant aspects of HAE [88]. Aesthetics was mentioned
more often by patients than by experts. On the other
hand, experts were more likely to mention the adverse
side effects of treatment. This finding supports the gen-
eral opinion that the clinician’s view of disease severity
does not necessarily match with the patient’s perception.
Recommendation 22
Health care providers should specifically address
factors known to affect quality of life with HAE
patients. Management of HAE should aim to
improve patients’ quality of life.
Level of Evidence: Low (100% Agree)
Strength of Recommendation: Strong (100% Agree)
Clinical considerations
Assessment of HAE control as it relates to the frequency,
duration and severity of attacks is not the only thing to
consider when monitoring patients. Data suggests that fac-
tors which relate to a patients qualify of life are important
when following patients with HAE. An international spe-
cific HRQoL questionnaire for adult patients with HAE
due to C1-inhibitor deficiency has been developed [89]
and is available for its use in clinical practice. The factors
that impact a patient’s QoL may be different than those
anticipated by the healthcare providers. Modifications
should be made to improve a patient’s QoL wherever pos-
sible. A small study demonstrated that self-administration
of pdC1-INH improved QOL on both physical and
psychological parameters. Patients were able to resume a
normal life without restriction [75]. Implementation of
self-administered therapy may lead to an improved QoL
by reducing the suffering caused by treating attacks too
late or leaving them untreated altogether. It was reinforced
at the meeting by the patient representatives that there are
still significant barriers to getting timely and appropriate
therapy at centres across Canada, likely from the lack of
awareness of HAE and the appropriate therapies available
for treatment. On-going research is required to determineadditional factors that may have impact HAE patients’
QoL.
Comprehensive care
Background
Comprehensive care of patientsis based on integration of
the organization, delivery, and management of services re-
lated to diagnosis, treatment, care, rehabilitation and
health promotion. The comprehensive care model has
been adopted by many rare disease groups and there is
evidence in other rare diseases that this model results in
better patient outcomes and reduced costs [71]. Haemo-
philia has used this model for decades. HAE is similar to
other rare blood disorders, including haemophilia, because
it is a chronic condition that is potentially life threatening
and requires a highly specialized, multidisciplinary team to
manage. However, although HAE is similar to other condi-
tions, it is also different enough to require its own frame-
work to meet the specific needs of these patients. The
recommendation to provide comprehensive care for
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published guidelines. The specific elements of comprehen-
sive care for HAE in Canada were published previously
and are listed in Table 4.
Recommendation 23
Comprehensive care should be available for all
patients with HAE.
Level of Evidence: Low (100% Agree)
Strength of Recommendation: Strong (100% Agree)
Clinical Considerations
Although the importance of the comprehensive care
model in HAE was recognized by the committee unani-
mously, and specific recommendations have existed with
respect to its requirements, this care model is not avail-
able to all patients with HAE in Canada. The provincial
and territorial model of health care funding makes im-
plementation of nationally uniform HAE comprehensive
care clinics challenging. Despite this, the fundamentals
of comprehensive care should be uniform across the
country and equally accessible across all geographic lo-
cations. Support should be provided by provincial and
territorial governments to ensure that proper standards
of care are being met. Treatments for HAE can be ex-
pensive; however inappropriate treatment of HAE may
be even more costly. It was recognised by the committee
that on-going monitoring of comprehensive care pro-
grams is essential to measure their impact on patients’
outcomes such as disease control, QoL and economic
effects.
Special populations
The committee recognized that management of HAE in
certain populations were not specifically addressed in
this guideline. These include paediatric HAE patients
and HAE patients during lactation and menstruation.
The recently published WAO document specifically ad-
dressed recommendations for the management of HAE-
1 and −2 in children [15]. An international consensus
and practice guidelines on the gynaecologic and obstet-
rical management of female patients with hereditary an-
gioedema caused by C1 inhibitor deficiency was recently
published by Caballero et al. [90] and readers are re-
ferred to those publications with the understanding that
they are not specific to Canadians.
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